Drug Development in the New Era: A Global Perspective
4th International conference on phase 1 and early phase clinical trials
March 1-2, 2018 | Hyatt Regency Hong Kong, Tsim Sha Tsui, 18 Hanoi Road, Kowloon, Hong Kong
Professor Raymond Cheung, MBBS(HK), MRCP(UK), FRCP (Edin, Glasg, Lond), FHKCP, FHKAM(Medicine), FAHA, FAAN, FESO, FRSM
Lee Man Chiu Professor in Neuroscience, Division of Neurology,
Department of Medicine, The University of Hong Kong, HKSAR, China
Professor Raymond Cheung obtained the medical degree from the University of Hong Kong in 1987 and obtained the degree of Doctor of Philosophy from the University of Western Ontario, London, Canada, in 1996. Professor Cheung a Specialist in Neurology. He joined the Department of Medicine of Queen Mary Hospital as a clinical staff in July 1989 and became an academic staff of the same Department in July 1996.
Professor Cheung’s main research interest is in stroke and cerebrovascular disease. He has conducted both experimental and clinical research studies. He was principal investigator of many multicenter international trials as well as several local clinical trials.
Atrial fibrillation is one of the major mechanisms of ischemic stroke. Results of clinical trials have documented to benefits and risks of long-term anticoagulation or antiplatelet inhibition. Choices of anticoagulation have been expended in recent years. Risk stratification systems are available to guide us in the choice between anticoagulation and antiplatelet therapy. Notwithstanding our current knowledge of the topic, there are important gaps for future research work.
Day One: Stroke Prevention in Atrial Fibrillation – Past, Present and Future